TD Cowen upgrades Starbucks stock rating on sales growth outlook

TD Cowen upgraded Starbucks to Buy from Hold and raised its price target to $120 from $106, implying upside from the current $105.95 share price. The firm cited improving sales revisions, margin recovery from labor investment and cost leverage, and confidence in management execution. The note follows Starbucks' fiscal Q2 2026 beat, with EPS of $0.50 versus $0.42 expected and revenue of $9.5 billion versus $9.12 billion.

Analysis

SBUX is the cleaner expression of this note: the market is still pricing a structurally broken traffic story, while the setup is really about operating leverage inflecting off a depressed base. If management can convert modest same-store sales stabilization into lower churn and fewer promo dollars, incremental margin recovery can outpace consensus quickly because labor and supply-cost benefits hit through a relatively fixed corporate structure. The key second-order effect is that a successful turn in SBUX tends to compress the valuation spread versus QSR peers, forcing reallocations out of defensive consumer names that have been treated as safer quality proxies.

The risk is that the bullish case is highly dependent on execution staying clean for several quarters, not one print. Any backslide in ticket size, weak U.S. traffic, or evidence that labor investments are not translating into throughput would break the leverage narrative fast and make the current multiple look fragile. The stock can still mean-revert lower if investors start demanding proof of sustained comps rather than paying for a far-dated earnings power story.

For NVDA, this is a sentiment tailwind more than a fundamental inflection, but it matters at the margin because China-access headlines can reopen a high-velocity earnings debate around H200 supply. The market will likely treat this as a near-term positive for order visibility, though the real constraint is not demand but policy durability; if the approval gets narrowed or reversed, the rally should fade just as quickly. The more durable implication is that any incremental China revenue can improve utilization and inventory digestion across the AI supply chain, supporting adjacent names even if the headline effect on NVDA is modest.

Key Decisions for Investors

• Long SBUX for 3-6 months via common stock or Jan-2027 calls; thesis is margin recovery + multiple expansion, with upside if the market rerates it from 'turnaround' to 'durable compounder'.
• Sell downside in SBUX by putting on a 6-9 month put spread if implied volatility is elevated; risk/reward favors monetizing the still-premium valuation while keeping exposure to execution upside.
• Relative value: long SBUX / short a slower-growth premium consumer staple or QSR peer basket over the next 1-2 quarters; if SBUX proves leverage, the valuation gap should narrow faster than the group.
• For NVDA, use any post-headline strength to add only tactically for 1-4 weeks; treat the move as policy-driven and fragile, with tight stops if China authorization headlines lose credibility.
• Consider a pair of long NVDA / short semi-equipment or AI-infrastructure beta if the market starts to overread the China story; the cleaner monetization is still in high-quality AI demand capture rather than broad beta.